During Q2 2023, BioMarin Pharmaceutical's revenues for the quarter has reached $595.3 million, a 12% YoY increase. The company's drug pipeline includes promising candidates for the treatment of rare ...
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the best growth stocks to buy according to analysts. On August 4, BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) released its Q2 2025 earnings. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback